NCT04506151 (SOPT) is a NA clinical trial of Sleep-Opt in Type 1 Diabetes, sponsored by University of Illinois at Chicago.

Who is sponsoring NCT04506151?

NCT04506151 is sponsored by University of Illinois at Chicago.

What drugs are being tested in NCT04506151?

Interventions in NCT04506151: Sleep-Opt, Healthy Living.

What condition does NCT04506151 study?

NCT04506151 studies Type 1 Diabetes.

Is NCT04506151 still recruiting?

NCT04506151 is currently active, enrolled. Last updated 15 August 2025.

Last reviewed 2025-08-15 · How we verify

NCT04506151: SOPT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sleep Optimization to Improve Glycemic Control in Adults With Type 1 Diabetes

Active, enrolled NA Last updated 15 August 2025

What this trial tests

NA trial testing Sleep-Opt in Type 1 Diabetes in 144 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

19 January 2021

Primary endpoint
21 December 2024

30 April 2026

Quick facts

Lead sponsor	University of Illinois at Chicago
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	144
Start date	19 January 2021
Primary completion	21 December 2024
Estimated completion	30 April 2026
Sites	1 location across United States

Drugs / interventions tested

Sleep-Opt
Healthy Living

Conditions studied

Type 1 Diabetes — all drugs for Type 1 Diabetes →

Sponsor

University of Illinois at Chicago

Who can join

Adults 18 to 65, any sex, with Type 1 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Up to 40% of adults with type 1 diabetes have insufficient sleep which is associated with negative health consequences including poor blood glucose control and greater diabetes complications. In this study, a sleep intervention (Sleep-Opt) that uses wearable sleep tracking technology, telephone coaching and informational content designed to improve sleep and glycemic control in working-age adults with type 1 diabetes. Sleep-Opt could lead to reduced development of diabetes complications and improve quality of life for adults with type 1 diabetes.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Association between sleep variability and time in range of glucose levels in patients with type 1 diabetes: Cross-sectional study.
Reutrakul S, Irsheed GA, Park M, Steffen AD, et al · · 2023 · cited 11× · PMID 37709596 · DOI 10.1016/j.sleh.2023.07.007
Multidimensional Sleep Health, Glycemic Control, and Self-reported Outcomes in Type 1 Diabetes: A Cross-sectional Study.
Abu Irsheed G, Steffen A, Martyn-Nemeth P, Park M, et al · · 2025 · cited 3× · PMID 39820481 · DOI 10.1210/clinem/dgaf032
Sleep optimization to improve glycemic control in adults with type 1 diabetes: study protocol for a randomized controlled parallel intervention trial.
Martyn-Nemeth P, Duffecy J, Quinn L, Reutrakul S, et al · · 2022 · cited 3× · PMID 35986415 · DOI 10.1186/s13063-022-06565-6
Blue Light Exposure During Sleep in Type 1 Diabetes: Impacts on Glycemic Control and Psychosocial Health.
Hong SJ, Pratuangtham S, Martyn-Nemeth P, Steffen AD, et al · · 2026 · PMID 42246173 · DOI 10.1111/jsr.70380

Verify or expand the search:

Other recruiting trials for Type 1 Diabetes

Currently open trials in the same condition.

NCT07061574 — A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New On · Phase 1, PHASE2 · recruiting
NCT07360080 — Long-Term Outcomes of Teplizumab in Routine Clinical Care · recruiting
NCT07457580 — Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) · recruiting
NCT07212179 — Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 · NA · recruiting
NCT07287943 — To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes. · NA · recruiting

Other University of Illinois at Chicago trials

Trials by the same sponsor.

NCT07498322 — Chicago Data-driven Opioid Use Disorder Screening, Engagement, Treatment and Planning System · NA · not yet recruiting
NCT07387705 — On Track for Wellness (OTW) Stepped Wedge Cluster Randomized Trial · Phase 1 · not yet recruiting
NCT07504120 — The Effect of Remotely Delivered Pilates on Physical , and Psychological Outcomes in Individuals With Multiple Sclerosis · NA · not yet recruiting
NCT07160582 — Cognitive-Motor Training for AD/ADRD Prevention · NA · not yet recruiting
NCT07498348 — Apple Watch Evaluation of Endodontics Occupational Stress · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04506151 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Illinois at Chicago
Last refreshed: 15 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04506151.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing